NASDAQ:AXLAAxcella Health Stock Price, Forecast & News

Axcella Health's stock was trading at $3.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXLA shares have increased by 64.2% and is now trading at $5.45. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axcella Health.

Axcella Health is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Axcella Health.

Axcella Health Inc (NASDAQ:AXLA) posted its earnings results on Monday, May, 11th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.21. View Axcella Health's earnings history.

4 Wall Street analysts have issued twelve-month price objectives for Axcella Health's stock. Their forecasts range from $10.00 to $25.00. On average, they expect Axcella Health's share price to reach $18.75 in the next twelve months. This suggests a possible upside of 244.0% from the stock's current price. View analysts' price targets for Axcella Health.

News headlines about AXLA stock have trended negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axcella Health earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAxcella Health.

Axcella Health saw a decrease in short interest in May. As of May 15th, there was short interest totaling 72,100 shares, a decrease of 18.0% from the April 30th total of 87,900 shares. Based on an average trading volume of 70,700 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the shares of the company are sold short. View Axcella Health's Current Options Chain.

Some companies that are related to Axcella Health include BioCryst Pharmaceuticals (BCRX), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Prevail Therapeutics (PRVL), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), MeiraGTx (MGTX) and Harpoon Therapeutics (HARP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Coty (COTY), Main Street Capital (MAIN), Myovant Sciences (MYOV), Triton International (TRTN), Carnival (CCL), NVIDIA (NVDA), Occidental Petroleum (OXY), Amarin (AMRN), vTv Therapeutics (VTVT) and Bristol-Myers Squibb (BMY).

(AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Axcella Health's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.48%), State Street Corp (0.50%), JPMorgan Chase & Co. (0.14%), Bank of New York Mellon Corp (0.10%), Chilton Investment Co. LLC (0.07%) and Wells Fargo & Company MN (0.05%). Company insiders that own Axcella Health stock include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet and Ventures Fund Iv LP Flagship. View institutional ownership trends for Axcella Health.

AXLA stock was sold by a variety of institutional investors in the last quarter, including Chilton Investment Co. LLC, and UBS Group AG. View insider buying and selling activity for Axcella Health.

AXLA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, and JPMorgan Chase & Co.. Company insiders that have bought Axcella Health stock in the last two years include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet, and Ventures Fund Iv LP Flagship. View insider buying and selling activity for Axcella Health.

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXLA stock can currently be purchased for approximately $5.45.

Axcella Health has a market capitalization of $186.32 million. The company earns $-59,040,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

The official website for Axcella Health is www.axcellahealth.com.

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.